Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-08-01 |
2024-06 |
-0.35 |
N/A |
N/A |
N/A |
2024-05-09 |
2024-03 |
-0.24 |
-0.32 |
-0.08 |
-33.33% |
2024-02-29 |
2023-12 |
-0.23 |
-0.16 |
0.07 |
30.43% |
2023-11-02 |
2023-09 |
-0.27 |
-0.18 |
0.09 |
33.33% |
2023-08-03 |
2023-06 |
-0.27 |
-0.11 |
0.16 |
59.26% |
2023-05-09 |
2023-03 |
-0.22 |
-0.24 |
-0.02 |
-9.09% |
Date |
Firm |
Action |
From |
To |
2023-09-10 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-31 |
Canaccord Genuity |
Upgrade |
Buy |
Buy |
2023-08-03 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-06-27 |
Wedbush |
Upgrade |
Outperform |
Outperform |
2023-06-26 |
Truist Securities |
Upgrade |
Buy |
Buy |
2023-06-26 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2023-11-05 |
EBSWORTH DAVID R |
Director |
844.64K |
Purchase |
2023-11-19 |
EDWARDS MARTIN |
Director |
144.80K |
Purchase |
2023-05-14 |
GUPTA RISHI |
Director |
0.00 |
Sale |
2023-10-19 |
HAHN MARK W. CPA |
Chief Financial Officer |
16.32M |
Stock Award(Grant) |
2023-05-14 |
ORBIMED ADVISORS, L.L.C. |
Unknown |
0.00 |
Sale |
2024-01-31 |
POLL CLAIRE LOUISE |
General Counsel |
2.80M |
Stock Gift |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
FMR, LLC |
7.11M |
150.30M |
13.72% |
2023-06-29 |
RA Capital Management, L.P. |
6.32M |
133.56M |
12.19% |
2023-06-29 |
NEA Management Company, LLC |
5.11M |
108.00M |
9.86% |
2023-06-29 |
Perceptive Advisors Llc |
4.40M |
92.96M |
8.49% |
2023-06-29 |
Wellington Management Group, LLP |
4.30M |
90.97M |
8.30% |
2023-06-29 |
Vivo Capital, LLC |
4.25M |
89.84M |
8.20% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-08-30 |
Fidelity Select Portfolios - Biotechnology |
1.43M |
27.79M |
2.76% |
2023-07-30 |
Vanguard Specialized-Health Care Fund |
1.16M |
25.63M |
2.24% |
2023-07-30 |
Federated Hermes Kaufmann Fund |
870.00K |
19.22M |
1.68% |
2023-07-30 |
Federated Hermes Kaufmann Small Cap Fund |
775.00K |
17.12M |
1.50% |
2023-07-30 |
Fidelity Advisor Biotechnology Fund |
768.07K |
16.97M |
1.48% |
2023-08-30 |
PGIM Jennison Health Sciences Fd |
699.24K |
13.59M |
1.35% |